TY - GEN
T1 - Effects of biologics on vascular function and Atherosclerosis associated with Rheumatoid Arthritis
AU - Kerekes, György
AU - Soltész, Pál
AU - Dér, Henriett
AU - Veres, Katalin
AU - Szabó, Zoltán
AU - Végvári, Anikó
AU - Shoenfeld, Yehuda
AU - Szekanecz, Zoltán
PY - 2009/9
Y1 - 2009/9
N2 - Endothelial dysfunction and accelerated atherosclerosis lead to increased cardiovascular morbidity and mortality in rheumatoid arthritis (RA). Sustained inflammation is a major risk factor. Apart from traditional vasculoprotective agents, biologics may also exert favorable effects on the vasculature. Indeed, tumor necrosis factor-α (TNF-α) inhibitors agents may transiently improve endothelial function. There are conflicting data regarding the effects of biologics on atherosclerosis and arterial stiffness. Infliximab stimulates the number and differentiation of endothelial progenitor cells that lead to vascular repair. There may be differences in the effects of TNF blockers on dyslipidemia, as long-term infliximab therapy may be proatherogenic, while some studies suggest that etanercept and adalimumab may exert beneficial effects on lipids. TNF blockers may decrease the incidence of cardiovascular events in RA. Preliminary data suggest that rituximab may also improve endothelial function and dyslipidemia. Further studies are needed to determine the net effects of biologics on the vasculature.
AB - Endothelial dysfunction and accelerated atherosclerosis lead to increased cardiovascular morbidity and mortality in rheumatoid arthritis (RA). Sustained inflammation is a major risk factor. Apart from traditional vasculoprotective agents, biologics may also exert favorable effects on the vasculature. Indeed, tumor necrosis factor-α (TNF-α) inhibitors agents may transiently improve endothelial function. There are conflicting data regarding the effects of biologics on atherosclerosis and arterial stiffness. Infliximab stimulates the number and differentiation of endothelial progenitor cells that lead to vascular repair. There may be differences in the effects of TNF blockers on dyslipidemia, as long-term infliximab therapy may be proatherogenic, while some studies suggest that etanercept and adalimumab may exert beneficial effects on lipids. TNF blockers may decrease the incidence of cardiovascular events in RA. Preliminary data suggest that rituximab may also improve endothelial function and dyslipidemia. Further studies are needed to determine the net effects of biologics on the vasculature.
KW - Arterial stiffness
KW - Atherosclerosis
KW - Carotid intima-media thickness
KW - Endothelial dysfunction
KW - Flow-mediated vasodilatation
KW - Lipid profile
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=69949148371&partnerID=8YFLogxK
U2 - 10.1111/j.1749-6632.2009.04645.x
DO - 10.1111/j.1749-6632.2009.04645.x
M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.conference???
C2 - 19758233
AN - SCOPUS:69949148371
SN - 9781573317627
T3 - Annals of the New York Academy of Sciences
SP - 814
EP - 821
BT - Contemporary Challenges in Autoimmunity
PB - Blackwell Publishing Inc.
ER -
